KlebNet: a One Health network bridging science and surveillance on antimicrobial resistant Klebsiella




Research Network: 2019-04-30 - 2021-06-30
Total sum awarded: €50 000

Klebsiella, particularly Klebsiella pneumoniae (hereafter, collectively called Kp) is an opportunistic pathogen of humans and animals that now tops the ‘urgent threat’ lists of CDC, ECDC and WHO due to high rates of multidrug resistance. Kp can also play a pioneer role in the amplification of novel AMR mechanisms acquired from environmental microbes, which can then spread to other important bacterial pathogens, as exemplified with KPC-2 or NDM-1 carbapenemases. Despite this, Kp does not currently feature as a target of surveillance efforts. Although Kp is generally viewed as ‘ubiquitous’, data on its distribution in healthy people, the environment, animals and the food chain are scarce, and the transmission of Kp and its AMR gene cargo between these potential sectors and hospitalised individuals is poorly understood. The KlebNet network is dedicated to identifying key knowledge gaps relating to Kp ecology and transmission, and to developing a One Health strategy for Kp surveillance. Strategy: Research on ecological distribution of Kp and on its transmission routes should, to be actionable, be guided by expected impact on implementation into surveillance and control programs. An optimal Kp surveillance strategy must be defined based on (1) Most advanced knowledge on the ecology, population biology and epidemiology of the pathogen, combined with (2) Actionability and practical aspects of the implementation of surveillance, in high-income as well as in low- and medium income countries (LMIC), and across sectors (clinical, animal, food). Objectives: (1) To review current knowledge on Kp reservoirs, population biology and transmission dynamics, and to identify and prioritise gaps where further research is required; and (2) To issue recommendations on how Kp surveillance should be implemented and harmonised across environment, animals, food and hospitals, including both technical and strategic considerations.

Read More
Read Less
  • Sylvain Brisse, Institut Pasteur, France (Coordinator)
  • Thierry Naas, University Paris-Diderot Medical School, INSERM, France (Observer)
  • Neil Woodford, Public Health England, United Kingdom (Observer)
  • Matthew Avison, University of Bristol, United Kingdom (Observer)
  • Stephen Baker, The Wellcome Trust, Vietnam (Observer)
  • Jean-Marc Collard, Institut Pasteur de Madagascar, Madagascar (Observer)
  • Nilton Lincopan, University of São Paulo, Brazil (Observer)
  • Sam Kariuki, Kenya Medical Research Institute, Kenya (Observer)
  • Jean-Yves Madec, ANSES, French Agency for Food, Environmental and Occupational Health & Safety, France (Observer)
  • Francesco Pomilio, Istituto Zooprofilattico Sperimentale, Italy (Observer)
  • Philippe Glaser, Institut Pasteur, France (Observer)
  • Edward Feil, University of Bath, United Kingdom (Observer)
  • Eva Møller Nielsen, Statens Serum Institute, Denmark (Observer)
  • Dearbhaile Morris, National University of Ireland Galway, Ireland (Observer)
  • Pascal Piveteau, Université de Bourgogne Dijon, France (Observer)
  • Davide Sassera, University of Pavia, Italy (Observer)
  • Radosław Izdebski, National Medicines Institute, Poland (Observer)
  • Nicola Holden, The James Hutton Institute, United Kingdom (Observer)
  • Ruth Zadoks, University of Glasgow, United Kingdom (Observer)
  • Rob Willems, University Medical Centre Utrecht, Netherlands (Observer)
  • Lulla Opatowski, Versailles Saint Quentin University, France (Observer)
  • Carla Rodriguez, Institut Pasteur, France (Observer)
  • Hajo Grundmann, University of Freiberg, Germany (Observer)
  • Arnfinn Sundsfjord, The Arctic University of Norway, Norway (Observer)
  • Ørjan Samuelsen, The Arctic University of Norway, Norway (Observer)
  • Iren Hoyland Löhr, Stavanger University Hospital, Norway (Observer)
  • Kathryn Holt, University of Melbourne, Australia (Observer)
  • Nick Thomson, The Wellcome Trust Sanger Institute, United Kingdom (Observer)
  • Sara Monteiro Pires, Technical University of Denmark, Denmark (Observer)
  • Willem van Schaik, University of Birmingham, United Kingdom (Observer)
  • Christian Giske, Karolinska Institutet, Sweden (Observer)